Anixa Biosciences
ANIX · NASDAQ
$2.68+$0.07 (+2.68%)TodayMarket closed ·
Prev close $2.61
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 14.2% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q3 FY26 | -$0.0877 | -$0.08 | +8.8% |
| Q2 FY26 | -$0.0893 | -$0.07 | +21.6% |
| Q1 FY26 | -$0.0969 | -$0.08 | +17.4% |
| Q4 FY25 | -$0.0893 | -$0.09 | −0.8% |
| Q3 FY25 | -$0.0918 | -$0.07 | +23.7% |
| Q2 FY25 | -$0.102 | -$0.09 | +11.8% |
| Q1 FY25 | -$0.102 | -$0.10 | +2.0% |
| Q4 FY24 | -$0.0867 | -$0.09 | −3.8% |
Earnings calls
- Special Call - Anixa Biosciences, Inc.
- Special Call - Anixa Biosciences, Inc.
- IAccess Alpha – Buyside Best Ideas Winter Virtual Conference 2024
- Special Call - Anixa Biosciences, Inc.
- H.C. Wainwright Virtual Global Life Sciences Conference
- B. Riley Securities Virtual Oncology Investor Conference
- Anixa Biosciences, Inc. (ANIX) CEO Amit Kumar on Outlook for 2019 Transcript
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.